The timing of the finding is no accident. Drugs that block PD-1, a receptor that tumors co-opt to disengage patrolling T cells, have reshaped oncology over the past decade; the underlying discovery earned James Allison and Tasuku Honjo the 2018 Nobel Prize in Physiology or Medicine, and checkpoint inhibitors are now approved across dozens of cancer indications. Yet even in diseases where they shine, durable responses occur in only a minority of patients, and oncologists still lack dependable tools to predict who will benefit. Sex has rarely featured in that calculation. Biomedical research has historically skewed toward male cells, male animals and male trial participants, often on the assumption that sex differences were noise to be averaged away — even though women mount generally stronger immune responses to infection and vaccination, at the price of higher rates of autoimmune disease. Funding agencies now require investigators to treat sex as a biological variable, and clinical analyses have hinted at divergent outcomes between men and women receiving checkpoint blockade. What has been missing is a mechanistic, cell-by-cell account of where those differences reside. The authors argue that cancer research remains largely focused on overall populations, overlooking the impact of sex, and their atlas is an attempt to close that gap across the disease spectrum rather than within a single tumor class.

Technically, the study rests on single-cell RNA sequencing, a method that dismantles a tissue into its constituent cells and reads the transcriptome of each one individually. Researchers dissociate tumor samples, capture thousands to hundreds of thousands of cells, barcode their messenger RNA, and sequence it in parallel; computational pipelines then cluster the resulting profiles into discrete cell types and subtypes, allowing investigators to census a tumor’s immune and stromal inhabitants with a granularity that bulk RNA sequencing — which averages signals across entire tissue fragments — cannot approach. Applied as a pan-cancer atlas, the method allowed the team to compile samples from fourteen human cancer types and systematically profile the tumor microenvironment in males and females side by side. Rather than asking how one cancer differs by sex, the design asks which features recur across the disease spectrum — a strategy that helps separate cancer-type idiosyncrasies from sex-linked programs that operate broadly. The census pointed, consistently, toward a specific triad of cell populations expanded in female tumors: myofibroblastic cancer-associated fibroblasts, SPP1-positive macrophages, and exhausted CD4-positive T cells, all of which are implicated in constructing an immune-resistant ecosystem.

Each member of that triad carries a specific mechanistic charge. Myofibroblastic cancer-associated fibroblasts, or myCAFs, are stromal cells that adopt a contractile, matrix-producing state; they lace tumors with dense extracellular matrix, stiffen the tissue, and can physically wall off T cells while secreting factors that suppress antitumor immunity. Macrophages, the tissue-resident scavengers of the immune system, are famously plastic — the same cell can promote tissue repair or stoke inflammation depending on the signals it receives, and within tumors, subsets of these cells are notorious for being co-opted by the malignancy itself. SPP1-positive macrophages, defined by high expression of the gene encoding secreted phosphoprotein 1 — better known as osteopontin, a secreted matricellular protein implicated in metastasis, cell survival signaling and immunosuppression — are increasingly recognized as markers and drivers of immunologically “cold” tumors that resist checkpoint blockade. Exhausted CD4-positive T cells, meanwhile, represent a dysfunctional state of the immune system’s helper arm: chronically stimulated, they lose productive effector function and express inhibitory receptors, contributing to a microenvironment with little for PD-1 blockade to reinvigorate. That all three populations were elevated in female tumors across fourteen cancer types suggests a convergent architecture of immune suppression assembled, at least in part, along sex-specific lines.

The atlas went beyond simply counting cells. Because single-cell data allow researchers to infer communication between cell types from co-expressed ligand-receptor pairs, the team mapped the crosstalk radiating from SPP1-positive macrophages and found it to be conspicuously sex-biased. In female tumors, the SPP1 macrophage module emerges as a signaling hub, wired into fibroblast and T-cell programs in ways that could plausibly coordinate the very triad the census had revealed: macrophages that recruit or polarize fibroblasts, fibroblasts that exclude or exhaust T cells, and T cells that in turn feed back into the suppressive loop. If the wiring diagram of a tumor differs by sex, the authors reasoned, so might its response to a therapy that depends on precisely that circuitry. The study’s title — “Pan-cancer single-cell atlas reveals sex-biased SPP1+ macrophage-associated crosstalk and its implications for immunotherapy” — compresses this logic into a single line: the sex difference is not merely a matter of cell counts, but a difference in the communication architecture of the tumor, with SPP1-positive macrophages sitting at a junction that carries unusually heavy traffic in females.

That hypothesis moved directly into the laboratory. The researchers compared anti-PD-1 immunotherapy responses between male and female mice and observed a clear divergence: the therapy was significantly more effective in males than in females, mirroring the direction of the human atlas findings. They then deployed a genetic model in which Spp1, the mouse equivalent of SPP1, was deleted specifically in macrophages. The intervention had a striking effect: macrophage-specific Spp1 knockout sensitized female mice to anti-PD-1 therapy, narrowing a therapeutic gap that had separated the sexes. The result matters because it crosses the line from correlation to causation. PD-1 blockade works by releasing a molecular brake on T cells, but it can only succeed if the surrounding microenvironment permits reinvigorated T cells to operate; the experiment indicates that in females, SPP1-producing macrophages are not passive bystanders but active enforcers of therapy resistance. Deleting their signature gene did not merely shift biomarkers — it changed therapeutic outcomes, the strongest form of evidence that a cell state is functionally responsible for a phenotype, at least within the bounds of a mouse model.

The work was grounded in real patients as well as large-scale datasets: tumor samples were obtained, with written informed consent, from colorectal and gastric cancer patients operated on at West China Hospital, and all animal procedures were approved by the institution’s ethics committee. For the authors, the implications reach beyond any single cell type. Their conclusion states plainly that sex shapes tumor microenvironment composition and drives divergent therapeutic responses, establishing sex as a critical variable in personalized cancer care and supporting sex-informed strategies to improve immunotherapeutic outcomes. In practical terms, that could mean stratifying patients by sex in immunotherapy trials, interpreting microenvironment biomarkers differently for men and women, or designing combination regimens — for instance, pairing checkpoint blockade with agents that target the SPP1/osteopontin axis or myCAF-driven suppression in female patients whose tumors are enriched for these features. It could also shape how existing drugs are dosed and sequenced, and how immune-related side effects are interpreted, since the immune system’s behavior in one sex cannot simply be mapped onto the other. Osteopontin-targeting approaches are already being explored in oncology, though none has yet reached routine clinical use.

Important caveats temper the excitement. The therapy experiments were performed in mice, and rodent immunology notoriously diverges from the human version; the atlas, however vast, is observational, and in humans it demonstrates association rather than causation. The study also does not settle the deeper question of what drives the sex bias — whether sex hormones such as estrogen and testosterone tune macrophage and fibroblast states, whether X- and Y-linked genes act directly within tumor-infiltrating cells, or whether environmental and behavioral factors layered on top of biology contribute. SPP1 itself is a multitasking protein with established roles in bone maintenance and wound healing, so systemic inhibition could carry liabilities that macrophage-specific genetic deletion in mice does not reveal. And the article is being released as an early, peer-reviewed accepted version that will later be replaced by the final record — a routine publishing practice that nonetheless invites the usual caution before findings harden into clinical doctrine. None of this undermines the central observation, but it frames the discovery as a starting point rather than a destination.

Even with those caveats, the study lands as a pointed challenge to a field that has long treated sex as a nuisance variable. An atlas of 1,662 tumors says otherwise: sex is written into the cellular architecture of cancer, into the crosstalk between macrophages, fibroblasts and T cells, and into the outcomes of the most celebrated therapies of the past decade. The next steps — testing whether SPP1-positive macrophages predict response in human trials, and whether silencing them rescues patients who currently do not benefit — will determine whether the finding becomes a footnote or a fixture of oncology practice. For now, the message is blunt: two patients with the same cancer type, sitting in the same clinic, may carry tumors built on different blueprints. Modern immunotherapy was engineered to release the brakes on T cells, but it will only work for everyone once it accounts for the fact that the road itself looks different depending on the driver’s sex.

Central to this discovery is the application of advanced three-dimensional (3D) imaging techniques, notably whole-mount immunofluorescence, which enabled the visualization of intricate cellular interplay within pancreatic lesions. Traditional two-dimensional (2D) microscopy has long confined scientists to fragmented representations of nerve fibers as isolated puncta, obscuring the true extent of their infiltration. The leap to 3D imaging unveiled a complex network of sympathetic nerves weaving through and around myCAFs and neoplastic structures, presenting an awe-inspiring panorama that redefines our understanding of neuro-stromal architecture in pancreatic tissue.

The interplay between myCAFs and nerves is not merely structural but profoundly functional. Fibroblasts within the tumor microenvironment are not passive bystanders; instead, they secrete signaling molecules that actively attract sympathetic nerve fibers, which are known to mediate the body’s fight-or-flight responses. These nerve fibers, in turn, release norepinephrine, a key neurotransmitter that binds adrenergic receptors on the myCAFs. This binding elicits a calcium influx within fibroblasts, a critical intracellular signal that potentiates their activation and perpetuates tumor-promoting functions.

This neuro-fibroblast interaction erects a pernicious feed-forward loop. Activated myCAFs enhance their signaling to recruit further nerve fibers, while the increased nervous presence escalates norepinephrine levels, thereby accelerating fibroblast activation. This cycle creates a pro-inflammatory, pro-tumorigenic niche, fostering a microenvironment that facilitates the transition from pancreatic inflammation to outright cancer. Such insights provide a compelling shift from viewing innervation as a late-stage tumor invasion phenomenon to understanding it as a foundational element in cancer genesis and progression.

The ramifications of these findings extend into therapeutic territory. Using murine models, the research team demonstrated that pharmacological disruption of the sympathetic nervous system via targeted neurotoxins markedly attenuated fibroblast activation and resulted in an almost 50% decrement in tumor growth. This pivotal experiment underscores the potential impact of therapeutically interrupting neural inputs to the tumor microenvironment as a strategy to hinder pancreatic cancer development at an incipient stage.

Moreover, the study implicates clinically approved drugs such as doxazosin—an adrenergic receptor antagonist traditionally used for hypertension and benign prostatic hyperplasia—as promising adjuvants in pancreatic cancer therapy. By blocking norepinephrine signaling, these agents could thwart the harmful neuro-fibroblast loop, thereby enhancing the efficacy of established chemotherapy and immunotherapy regimens. This repurposing approach could accelerate the translation of laboratory discoveries into clinical practice, bypassing many hurdles associated with entirely new drug development.

The research’s emphasis on the sympathetic nervous system—a critical player in stress and homeostasis—further raises intriguing questions regarding the systemic influences on pancreatic pathology. The fight-or-flight mediated release of neurotransmitters, long associated with acute physiological responses, appears to have a sinister counterpart in oncology, where its aberrant activation may precipitate oncogenic remodeling in pancreatic stroma. This paradigm shift opens avenues for exploring how lifestyle factors, stress, and neuroendocrine regulation intersect with tumor biology.

Importantly, the team’s dissection of fibroblast-neuron communication enhances the broader understanding of tumor microenvironment plasticity. MyCAFs, characterized by their myofibroblastic phenotype, have emerged increasingly as pivotal architects within the stromal compartment, sculpting the extracellular matrix, modulating immune cell infiltration, and now, as demonstrated, orchestrating neural infiltration. This expanded functional repertoire underscores the necessity of targeting stromal components alongside cancer cells for comprehensive therapeutic attack.

The study’s reliance on sophisticated imaging and molecular techniques paves the way for future investigations into the spatial and temporal dynamics of tumor innervation. By resolving the 3D architecture and signaling cascades in situ, researchers can better comprehend how cellular heterogeneity and microenvironmental cues synchronize to drive pancreatic carcinogenesis. This holistic perspective is crucial for the rational design of interventions that disrupt pathological cell-cell communication networks.

Looking ahead, the research team envisions an intensive effort to delineate the molecular mediators bridging myCAFs and nerves, aiming to identify druggable targets that can sever their nefarious dialogue. Supported by philanthropic organizations such as the Lustgarten Foundation and the Pancreatic Cancer Action Network, these endeavors seek to translate molecular insights into tangible clinical benefits, potentially improving the grim prognosis associated with pancreatic cancer.

The revelation that neuroplasticity—in this context, the nerve remodeling induced by myofibroblasts—serves as a catalyst for pancreatic inflammation and carcinogenesis breaks new ground in cancer biology. It highlights the interdependence of diverse cell types within the tumor microenvironment and the critical impact of nervous system components in disease progression, heralding a holistic approach to cancer treatment that accounts for neural contributions.

In sum, this research from CSHL reframes pancreatic cancer as not solely a cellular aberration confined to epithelial cells but as an orchestrated pathological process involving intricate neuro-stromal crosstalk. The identification of this neuro-fibroblast cycle as a driver of tumor landscape morphogenesis opens a promising frontier for interventions designed to dismantle the supportive niche tumors exploit for survival and expansion.

Subject of Research: Pancreatic cancer development and the role of sympathetic nervous system and myofibroblastic cancer-associated fibroblasts (myCAFs) in tumor microenvironment remodeling.

Article Title: Myofibroblasts induce neuroplasticity to promote pancreatic inflammation and cancer progression

News Publication Date: 9-Feb-2026

Web References: http://dx.doi.org/10.1158/2159-8290.CD-25-1337

Image Credits: Tuveson lab/Cold Spring Harbor Laboratory

Keywords: Fibroblasts, Pancreatic cancer, Adrenergic receptor signaling, FGF pathway, Axons, Paracrine signaling